- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lasa Supergenerics has announced a board meeting on May 29, 2025, to consider the financial results for the quarter and half-year.
The company’s standalone financials reveal significant asset growth but lack clear consolidated revenue details. The sale of two manufacturing units at ₹9.6 Cr affected revenue reporting. For FY2025, Lasa posted a net loss of ₹19.38 Cr, slightly higher than the previous year’s ₹19.11 Cr loss. Depreciation rose to ₹12.29 Cr, driven by asset expansion and impairment charges including a ₹23.91 Cr loss on unit sales. EPS data was not disclosed.
Operational costs increased with finance costs up to ₹2.69 Cr from ₹1.93 Cr due to higher borrowings. Provision for doubtful debts at ₹6.45 Cr signals pressure on receivables. Inventory levels saw a marked rise, hinting at stock accumulation or capacity buildup. An exceptional ₹9.22 Cr non-operating expense was partially offset by ₹2.20 Cr government grants. Despite an operating profit before working capital changes of ₹9.15 Cr, negative cash flows from operations reflect working capital inefficiencies.
On the balance sheet, equity capital and reserves swelled to ₹1250 Cr and ₹1333 Cr respectively, mainly from revaluation and capitalization of intangibles (₹320 Cr) and fixed assets (₹348 Cr). However, current borrowings jumped from ₹22 Cr to ₹162 Cr, increasing short-term leverage. Cash reserves shrank to ₹2.75 Cr, with operating cash flows negative at ₹2.82 Cr.
Post-quarter, a factory fire caused substantial uninsured inventory and asset losses, raising operational risks. Management is working on recovery and funding strategies but maintains going concern status.
Lasa is navigating asset and working capital challenges amid restructuring with near-term cash flow and debt pressures. Retail investors should stay cautious, watching for recovery execution and improvements in cash generation before considering exposure.